input from S.J.A. and A.K.S.Competing interests:A.K.S. reports
compensation for consulting and/or scientific advisory board
(SAB) membership from Merck, Honeycomb Biotechnologies,
Cellarity, Repertoire Immune Medicines, Third Rock Ventures,
Ochre Bio, and Dahlia Biosciences unrelated to this work. A.Y.R. is
a co-founder of Sonoma Biotherapeutics and Vedanta Biosciences.
He is an SAB member and holds stock options in Sonoma
Biotherapeutics, RAPT Therapeutics, and Vedanta Biosciences
and holds intellectual property for therapeutic antibody depleting
Tregslicensed to Takeda.Data and materials availability:All data
are available in the main text or supplementary materials.
scRNA-seq data is available from the Gene Expression Omnibus,
under accession number GSE173227.SUPPLEMENTARY MATERIALS
science.sciencemag.org/content/373/6552/eabe5146/suppl/DC1
Figs. S1 to S10Tables S1 and S2
MDAR Reproducibility Checklist
Movies S1 and S2
Data S1 and S226 August 2020; accepted 19 May 2021
10.1126/science.abe5146Jacobsenet al.,Science 373 , eabe5146 (2021) 16 July 2021 13 of 13
RESEARCH | RESEARCH ARTICLE